We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Study of Cell Therapeutics' Tosedostat for Elderly Patients with AML or High-Risk MDS Now Enrolling

News   Jun 19, 2012

 
Study of Cell Therapeutics' Tosedostat for Elderly Patients with AML or High-Risk MDS Now Enrolling
 
 
 

RELATED ARTICLES

Prostate Cancer "Super Responders" Live for 2 Years on Immunotherapy

News

A major clinical trial shows that some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy.

READ MORE

Safety and Efficacy Results From CRISPR/Cas9 Human Clinical Trials Are Positive

News

CRISPR Therapeutics and Vertex Pharmaceuticals have announced their interim safety and efficacy results from the CTX001 CRISPR/Cas9 gene-editing human clinical trials - and they're promising.

READ MORE

Collaboration Aims To Improve Efficacy of Lung Cancer Drug

News

The University of Barcelona and Hospital ClĂ­nic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug used to treat lung cancer.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE